George, P., Dasyam, N., Giunti, G., Mester, B., Bauer, E., Andrews, B., . . . Weinkove, R. (2020). Third-generation anti-CD19 chimeric antigen receptor T-cells incorporating a TLR2 domain for relapsed or refractory B-cell lymphoma: A phase I clinical trial protocol (ENABLE). BMJ Open.
Citación estilo ChicagoGeorge, Philip, et al. "Third-generation Anti-CD19 Chimeric Antigen Receptor T-cells Incorporating a TLR2 Domain for Relapsed or Refractory B-cell Lymphoma: A Phase I Clinical Trial Protocol (ENABLE)." BMJ Open 2020.
Cita MLAGeorge, Philip, et al. "Third-generation Anti-CD19 Chimeric Antigen Receptor T-cells Incorporating a TLR2 Domain for Relapsed or Refractory B-cell Lymphoma: A Phase I Clinical Trial Protocol (ENABLE)." BMJ Open 2020.